{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:51:50Z","timestamp":1765889510132,"version":"build-2065373602"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023YFS0256"],"award-info":[{"award-number":["2023YFS0256"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2021HXFH007"],"award-info":[{"award-number":["2021HXFH007"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1245\/s10434-025-17981-8","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T23:27:28Z","timestamp":1754263648000},"page":"10294-10304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the Impact of 5-Alpha Reductase Inhibitors on Bladder Cancer: Insights from a Large-Scale Prospective Cohort Study"],"prefix":"10.1245","volume":"32","author":[{"given":"Lede","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8246-853X","authenticated-orcid":false,"given":"Xianding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"issue":"1","key":"17981_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tau.2018.09.11","volume":"8","author":"MGK Cumberbatch","year":"2019","unstructured":"Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5\u201311.","journal-title":"Transl Androl Urol."},{"issue":"3","key":"17981_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/iju.IJU_320_19","volume":"36","author":"HK Moorthy","year":"2020","unstructured":"Moorthy HK, Prabhu GGL, Venugopal P. Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol. 2020;36(3):171\u20138.","journal-title":"Indian J Urol."},{"issue":"3","key":"17981_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.eururo.2015.08.029","volume":"69","author":"EE Morales","year":"2016","unstructured":"Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. 2016;69(3):407\u201310.","journal-title":"Eur Urol."},{"issue":"6","key":"17981_CR4","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"17981_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353.","journal-title":"Int J Cancer."},{"issue":"2","key":"17981_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5534\/wjmh.230137","volume":"42","author":"JH Pyun","year":"2024","unstructured":"Pyun JH, Son NH, Ko YH, Kim SW, Kim H, Bae YJ. The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study. World J Mens Health. 2024;42(2):460\u20136.","journal-title":"World J Mens Health."},{"issue":"10","key":"17981_CR7","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00345-023-04551-4","volume":"41","author":"F Del Giudice","year":"2023","unstructured":"Del Giudice F, Belladelli F, Glover F, Basran S, Li S, Mulloy E, Pradere B, Soria F, Krajewski W, Nair R, Muncey W, Seranio N, Eisenberg ML. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (\u03b1-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data. World J Urol. 2023;41(10):2783\u201391.","journal-title":"World J Urol."},{"issue":"5","key":"17981_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13667","volume":"6","author":"MH An","year":"2023","unstructured":"An MH, Kim MS, Kim C, Noh TI, Joo KJ, Lee DH, Yi KH, Kwak JW, Hwang TH, Park RW, Kang SH. Association of 5\u03b1-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea. JAMA Netw Open. 2023;6(5):e2313667.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"17981_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1055-9965.EPI-22-1109","volume":"32","author":"N Doherty","year":"2023","unstructured":"Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B. 5\u03b1-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev. 2023;32(3):428\u201334.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"2","key":"17981_CR10","doi-asserted-by":"publisher","first-page":"314.e1","DOI":"10.1016\/j.clgc.2022.10.014","volume":"21","author":"H Garg","year":"2023","unstructured":"Garg H, Wheeler KM, Dursun F, Cooper RE, Pruthi DK, Kaushik D, Thompson IM, Svatek RS, Liss MA. Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. Clin Genitourin Cancer. 2023;21(2):314.e1-314.e7.","journal-title":"Clin Genitourin Cancer."},{"issue":"1","key":"17981_CR11","doi-asserted-by":"publisher","first-page":"50.e11","DOI":"10.1016\/j.urolonc.2022.09.004","volume":"41","author":"S Dekalo","year":"2023","unstructured":"Dekalo S, McArthur E, Campbell J, Ordon M, Power N, Welk B. 5\u03b1-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urol Oncol. 2023;41(1):50.e11-50.e17.","journal-title":"Urol Oncol."},{"issue":"1","key":"17981_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejso.2022.06.005","volume":"49","author":"L Lin","year":"2023","unstructured":"Lin L, Guo X, Ma Y, Zhu J, Li X. Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis. Eur J Surg Oncol. 2023;49(1):29\u201338.","journal-title":"Eur J Surg Oncol."},{"key":"17981_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2250","volume":"357","author":"HM Dehbi","year":"2017","unstructured":"Dehbi HM, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ. 2017;357:j2250.","journal-title":"BMJ."},{"issue":"4","key":"17981_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.juro.2018.04.082","volume":"200","author":"VJ M\u00e4kel\u00e4","year":"2018","unstructured":"M\u00e4kel\u00e4 VJ, Kotsar A, Tammela TLJ, Murtola TJ. Bladder Cancer Survival of Men Receiving 5\u03b1-Reductase Inhibitors. J Urol. 2018;200(4):743\u20138.","journal-title":"J Urol."},{"issue":"2","key":"17981_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","volume":"197","author":"M Shiota","year":"2017","unstructured":"Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5\u03b1-Reductase Inhibitor. J Urol. 2017;197(2):308\u201313.","journal-title":"J Urol."},{"key":"17981_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/BLC-190262","volume":"6","author":"M Al-Hogbani","year":"2020","unstructured":"Al-Hogbani M, Gilbert S, Lodde M, Fradet Y, Toren P. Does 5-alpha reductase inhibitor use improve the efficacy of intravesical bacille calmette-gu&eacute;rin (BCG) for non-muscle invasive bladder cancer? Bladder Cancer. 2020;6:63\u20139.","journal-title":"Bladder Cancer."},{"issue":"6","key":"17981_CR17","doi-asserted-by":"publisher","first-page":"e1122","DOI":"10.1016\/j.clgc.2019.07.016","volume":"17","author":"C McMartin","year":"2019","unstructured":"McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P. Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? Clin Genitourin Cancer. 2019;17(6):e1122\u20138.","journal-title":"Clin Genitourin Cancer."},{"issue":"3","key":"17981_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.23736\/S2724-6051.19.03563-X","volume":"74","author":"AL Pastore","year":"2022","unstructured":"Pastore AL, Fuschi A, de Nunzio C, Balzarro M, Al Salhi Y, Velotti G, Martoccia A, Capone L, Amigoni N, Falsaperla M, Mattia C, Artibani W, Tubaro A, Carbone A. Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicenter study. Minerva Urol Nephrol. 2022;74(3):337\u201343.","journal-title":"Minerva Urol Nephrol."},{"issue":"1","key":"17981_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12885-020-07373-4","volume":"20","author":"CS Wang","year":"2020","unstructured":"Wang CS, Li CC, Juan YS, Wu WJ, Lee HY. 5\u03b1-reductase inhibitors impact prognosis of urothelial carcinoma. BMC Cancer. 2020;20(1):872.","journal-title":"BMC Cancer."},{"issue":"4","key":"17981_CR20","first-page":"371","volume":"19","author":"MD Wissing","year":"2021","unstructured":"Wissing MD, O\u2019Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec. Canada Clin Genitourin Cancer. 2021;19(4):371-371.e9.","journal-title":"Canada. Clin Genitourin Cancer."},{"issue":"6","key":"17981_CR21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00345-018-2504-3","volume":"37","author":"M Moschini","year":"2019","unstructured":"Moschini M, Zaffuto E, Karakiewicz P, Mattei A, Gandaglia G, Fossati N, Montorsi F, Briganti A, Shariat SF. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. World J Urol. 2019;37(6):1127\u201335.","journal-title":"World J Urol."},{"key":"17981_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.784627","volume":"11","author":"P Xiang","year":"2021","unstructured":"Xiang P, Du Z, Hao Y, Guan D, Liu D, Yan W, Wang M, Liu Y, Ping H. Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:784627.","journal-title":"Front Oncol."},{"issue":"1","key":"17981_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-020-02308-w","volume":"18","author":"W Fang","year":"2020","unstructured":"Fang W, Yang ZY, Chen TY, Shen XF, Zhang C. Ethnicity and survival in bladder cancer: a population-based study based on the SEER database. J Transl Med. 2020;18(1):145.","journal-title":"J Transl Med."},{"issue":"30","key":"17981_CR24","doi-asserted-by":"publisher","first-page":"29860","DOI":"10.18632\/oncotarget.5007","volume":"6","author":"T Kawahara","year":"2015","unstructured":"Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, Netto GJ, Zheng Y, Miyamoto H. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget. 2015;6(30):29860\u201376.","journal-title":"Oncotarget."},{"issue":"6","key":"17981_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1535-7163.MCT-17-0786","volume":"17","author":"S Inoue","year":"2018","unstructured":"Inoue S, Ide H, Mizushima T, Jiang G, Netto GJ, Gotoh M, Miyamoto H. Nuclear Factor-\u03baB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling. Mol Cancer Ther. 2018;17(6):1303\u201314.","journal-title":"Mol Cancer Ther."},{"issue":"7","key":"17981_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/jnci\/djk113","volume":"99","author":"H Miyamoto","year":"2007","unstructured":"Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558\u201368.","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"17981_CR27","first-page":"6893","volume":"37","author":"CC Chen","year":"2017","unstructured":"Chen CC, Huang CP, Tsai YT, Hseih TF, Shyr CR. The Genomic Alterations of 5\u03b1-Reductases and Their Inhibitor Finasteride\u2019s Effect in Bladder Cancer. Anticancer Res. 2017;37(12):6893\u20138.","journal-title":"Anticancer Res."},{"key":"17981_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lfs.2017.09.029","volume":"190","author":"S Hata","year":"2017","unstructured":"Hata S, Ise K, Azmahani A, Konosu-Fukaya S, McNamara KM, Fujishima F, Shimada K, Mitsuzuka K, Arai Y, Sasano H, Nakamura Y. Expression of AR, 5\u03b1R1 and 5\u03b1R2 in bladder urothelial carcinoma and relationship to clinicopathological factors. Life Sci. 2017;190:15\u201320.","journal-title":"Life Sci."},{"issue":"9","key":"17981_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41585-023-00761-y","volume":"20","author":"J Chen","year":"2023","unstructured":"Chen J, Huang CP, Quan C, Zu X, Ou Z, Tsai YC, Messing E, Yeh S, Chang C. The androgen receptor in bladder cancer. Nat Rev Urol. 2023;20(9):560\u201374.","journal-title":"Nat Rev Urol."},{"issue":"51","key":"17981_CR30","doi-asserted-by":"publisher","first-page":"E3588","DOI":"10.1073\/pnas.1113960109","volume":"109","author":"JB Overdevest","year":"2012","unstructured":"Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A. 2012;109(51):E3588\u201396.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"17981_CR31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/cancers16040746","volume":"16","author":"D Sundi","year":"2024","unstructured":"Sundi D, Collier KA, Yang Y, Diaz DA, Pohar KS, Singer EA, Gupta S, Carson WE 3rd, Clinton SK, Li Z, Messing EM. Roles of Androgen Receptor Signaling in Urothelial Carcinoma. Cancers (Basel). 2024;16(4):746.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"17981_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948467","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Sun Y, Ou Z, Yeh S, Huang CP, You B, Tsai YC, Sheu TJ, Zu X, Chang C. Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion. EMBO Rep. 2020;21(4):e48467.","journal-title":"EMBO Rep."},{"issue":"7","key":"17981_CR33","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41418-021-00743-w","volume":"28","author":"G Deng","year":"2021","unstructured":"Deng G, Wang R, Sun Y, Huang CP, Yeh S, You B, Feng C, Li G, Ma S, Chang C. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR\/circRNA-ARC1\/miR-125b-2-3p or miR-4736\/PPAR\u03b3\/MMP-9 signals. Cell Death Differ. 2021;28(7):2145\u201359.","journal-title":"Cell Death Differ."},{"issue":"3","key":"17981_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215\u201324.","journal-title":"N Engl J Med."},{"issue":"13","key":"17981_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. REDUCE Study Group Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192\u2013202.","journal-title":"N Engl J Med."},{"issue":"3","key":"17981_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","volume":"31","author":"R Sendor","year":"2022","unstructured":"Sendor R, St\u00fcrmer T. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31(3):261\u20139.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"17981_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.23736\/S2724-6051.22.04953-9","volume":"75","author":"R Contieri","year":"2023","unstructured":"Contieri R, Hurle R, Paciotti M, Casale P, Saita A, Porpiglia F, Fiori C, Barone B, Crocetto F, Lucarelli G, Busetto GM, Del Giudice F, Maggi M, Cantiello F, Damiano R, Borghesi M, Bove P, Bertolo R, Papalia R, Mari A, Luzzago S, Mistretta FA, Soria F, Gontero P, Marchioni M, la Civita E, Terracciano D, Russo GI, Schips L, Perdona S, Mirone V, Tataru OS, Musi G, Vartolomei MD, Autorino R, Montanari E, de Cobelli O, Ferro M. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. Minerva Urol Nephrol. 2023;75(2):180\u20137.","journal-title":"Minerva Urol Nephrol."},{"issue":"1","key":"17981_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00345-024-04937-y","volume":"42","author":"L Lin","year":"2024","unstructured":"Lin L, Ma Y, Li Z, Liu L, Hu Q, Zhou L. Genetic susceptibility of urolithiasis: comprehensive results from genome-wide analysis. World J Urol. 2024;42(1):230.","journal-title":"World J Urol."},{"issue":"1","key":"17981_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13098-024-01404-x","volume":"16","author":"X Zeng","year":"2024","unstructured":"Zeng X, Li Z, Lin L, Wei X. Assessment of glycemic susceptibility across multiple urological and reproductive disorders. Diabetol Metab Syndr. 2024;16(1):162.","journal-title":"Diabetol Metab Syndr."},{"issue":"1","key":"17981_CR40","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s42003-024-06114-8","volume":"7","author":"L Lin","year":"2024","unstructured":"Lin L, Tang Y, Ning K, Li X, Hu X. Investigating the causal associations between metabolic biomarkers and the risk of kidney cancer. Commun Biol. 2024;7(1):398.","journal-title":"Commun Biol."},{"issue":"3","key":"17981_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3797","volume":"40","author":"L Lin","year":"2024","unstructured":"Lin L, Ning K, Xiang L, Peng L, Li X. SGLT2 inhibition and three urological cancers: Up-to-date results. Diabetes Metab Res Rev. 2024;40(3):e3797.","journal-title":"Diabetes Metab Res Rev."},{"issue":"10","key":"17981_CR42","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s40618-023-02060-0","volume":"46","author":"L Lin","year":"2023","unstructured":"Lin L, Wang W, Xiao K, Guo X, Zhou L. Genetically elevated bioavailable testosterone level was associated with the occurrence of benign prostatic hyperplasia. J Endocrinol Invest. 2023;46(10):2095\u2013102.","journal-title":"J Endocrinol Invest."},{"issue":"3","key":"17981_CR43","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1007\/s11357-025-01623-8","volume":"47","author":"L Lin","year":"2025","unstructured":"Lin L, Li Z, Chen K, Shao Y, Li X. Uncovering somatic genetic drivers in prostate cancer through comprehensive genome-wide analysis. Geroscience. 2025;47(3):5039\u201356.","journal-title":"Geroscience."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17981-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:40Z","timestamp":1762352260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17981-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["17981"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17981-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,8,3]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lede Lin, Zhihong Liu, Yaxiong Tang, Tao Lin, Xiang Li, and Xianding Wang have no conflicts of interest or financial ties to declare that may be relevant to the contents of this study.Ethics approval and consent to participateNot applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}